New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 17, 2012
09:29 EDTABT, RIGLRigel Pharmaceuticals price target lowered to $8 from $15 at Roth Capital
Roth Capital lowered its target on Rigel after the company's rheumatoid arthritis treatment fostamatinib did not demonstrate equivalence versus Abbott's (ABT) Humira in a Phase II test. The firm reduced its estimates for fostamatinib but maintains a Buy rating on the stock based on valuation.
News For RIGL;ABT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 22, 2015
08:09 EDTRIGLJefferies views Rigel as rare biotech stock
Subscribe for More Information
May 21, 2015
07:37 EDTABTPfizer replaces AbbVie as top global pharma pick at Jefferies
Subscribe for More Information
May 19, 2015
12:30 EDTRIGLRigel Pharmaceuticals management to meet with Jefferies
Subscribe for More Information
08:02 EDTABTAbbott announces CE Mark for new advancement of Absorb stent system
Subscribe for More Information
May 18, 2015
11:23 EDTABTFitch downgrades Abbott's L-T IDR to A; outlook revised to stable
Subscribe for More Information
May 14, 2015
09:41 EDTABTLeerink medical devices analyst holds a cardiology luncheon meeting
Subscribe for More Information
May 11, 2015
10:30 EDTABTAbbott names Brian Yoor as SVP, Finance and CFO
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use